Flubromazolam
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a synthetic depressant of the benzodiazepine class. It is the triazolo-structural analog of flubromazepam, among the most potent designer benzodiazepines identified to date.[1] Flubromazolam is a positive allosteric modulator of GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, alcohol, barbiturates +2 morebenzodiazepines, alcohol, barbiturates, z-drugs, gabapentinoids show less
Synthesized as a pharmaceutical candidate during the 1970s–1980s, flubromazolam was never advanced to clinical trials or approved for therapeutic use.[3] It appeared on online research chemical markets from 2014 and was rapidly flagged as a public health concern due to sub-milligram active doses that are extremely difficult to measure accurately.[4][5] The compound was placed in UN Schedule IV in 2021 and in permanent US Schedule I effective April 2026.
Subjective effects include heavy sedation, anxiolysis, muscle relaxation, amnesia, and euphoria. The experience is defined by its depth and duration — a slow-building, all-encompassing suppression of arousal and anxiety accompanied by pronounced memory blackouts that distinguish it from shorter-acting benzodiazepines.[3] Delusions of sobriety, compulsive redosing, and disinhibition are characteristic unsought effects.
Flubromazolam produces rapid physical dependence, and abrupt cessation carries seizure risk — no established equivalence dose exists for clinical withdrawal management.[6] The sub-milligram active dose range creates a narrow margin between desired and dangerous effects; synergistic respiratory depression with opioids drives nearly all documented fatalities.[7] The entire published human pharmacokinetic dataset derives from a single researcher self-experiment, and no controlled toxicity studies have been conducted.[4]
History[edit]
Discovery
Flubromazolam was synthesized during the 1970s–1980s wave of triazolobenzodiazepine development by pharmaceutical companies seeking improved sedative-hypnotics. The compound, sometimes designated JYI-73, was covered under European Patent EP 0072029 B1 (registered 1978, published 1986).citation needed It was never advanced beyond early-stage evaluation — no clinical trials were conducted, and no country approved it for therapeutic use.[3]
Emergence as a designer benzodiazepine
Designer benzodiazepines as a class began appearing on online research chemical markets around 2012.[4] Flubromazolam was first offered online from 2014[4] and was formally characterized in forensic toxicology literature by Huppertz and colleagues in 2015.[8] Moosmann, King, and Auwärter flagged it alongside clonazolam as particularly dangerous: compounds capable of producing strong sedation and amnesia at doses as low as 0.5 mg — doses "extremely difficult to measure for users handling bulk materials".[5]
Scheduling
International scheduling followed rapidly. Switzerland and Sweden controlled the compound by late 2015,citation needed the United Kingdom classified it as Class C, Schedule 1 in May 2017,citation needed and Australia listed it as Schedule 9 from approximately 2016.[9] The UN Commission on Narcotic Drugs placed flubromazolam in Schedule IV of the 1971 Convention in June 2021,[10] and the United States finalized permanent Schedule I placement effective April 2026.[10]
The name flubromazolam follows standard benzodiazepine nomenclature: "flu" for the fluorine substituent, "bro" for bromine, "maz" from the benzodiazepine core, and the "-olam" suffix denoting a triazole-fused ring system shared with triazolam, alprazolam, and Clonazolam. No widely adopted street names have emerged, reflecting distribution through online research chemical vendors rather than traditional street-level markets.
Chemistry[edit]
Structural class
Flubromazolam is a triazolobenzodiazepine — a benzodiazepine in which a 1,2,4-triazole ring is fused to the diazepine ring, incorporating a methyl group at the triazole nitrogen. This modification, shared with triazolam and alprazolam, is associated with increased potency relative to non-fused benzodiazepines.[11] Flubromazolam is specifically the triazolo-structural analog of flubromazepam, formed by fusion of the methyl-triazole ring onto the parent scaffold.
The compound carries a bromine at the 8-position and a 2-fluorophenyl group at the 6-position. These halogen substitutions distinguish it from triazolam (which carries chlorine at both positions) and contribute to its pharmacological profile.[11]
Molecular properties
| Molecular formula | C₁₇H₁₂BrFN₄ |
| Molecular weight | 371.2 g/mol |
The molecular scaffold consists of a seven-membered diazepine ring fused to a benzene ring, with the additional triazole creating a tricyclic system. The bromine and fluorine substituents are both electron-withdrawing halogens that influence receptor binding and metabolic stability.
Stereochemistry
Flubromazolam contains no chirality centres and exists as a single structural form. No stereoisomeric considerations apply.
Physical properties
No published data on melting point, solubility, or crystal form exist. High lipophilicity is implied by the compound's high plasma protein binding and large volume of distribution.[12] The halogenated aromatic system is consistent with low water solubility and high membrane permeability, typical of the triazolobenzodiazepine class.
Pharmacology[edit]
Mechanism of action
Flubromazolam acts as a positive allosteric modulator of GABA-A receptors. It binds to the interface between α and γ subunits of the GABA-A complex, amplifying the effect of the brain's main inhibitory neurotransmitter (GABA) by increasing chloride ion flow into neurons.[2][13] This mechanism — boosting existing inhibitory signals rather than directly activating the receptor — produces sedation, anxiety relief, muscle relaxation, memory suppression, and anticonvulsant effects.
No binding affinity data specific to flubromazolam have been published.safety citation needed Its exceptional potency — pharmacological effects at oral doses of 0.5 mg[3] — is inferred from its triazolobenzodiazepine structure and from modelling that predicts this subclass as the most potent among designer benzodiazepines.[1]
A single 0.5 mg oral dose produced sedation lasting more than 10 hours and partial amnesia exceeding 24 hours in the only published human experiment.[3][5]
Pharmacokinetics
The only published human pharmacokinetic data come from a single self-experiment in which a researcher ingested 0.5 mg orally.[4] Peak blood concentration was reached at approximately 8 hours — unusually slow for a benzodiazepine — with a terminal half-life estimated at 10–20 hours. The parent compound was detectable in urine for up to 6.5 days and the primary metabolite for up to 8 days.[4]
The liver enzymes CYP3A4 and CYP3A5 are the primary metabolic pathway, producing hydroxylated metabolites that are further processed into glucuronide conjugates.[12] Predicted liver clearance is low, consistent with the long half-life.[12] Metabolites confirmed in both laboratory and human studies serve as the primary forensic detection targets.[8][4]
All human pharmacokinetic values derive from a single subject. Individual variation in liver enzyme activity, body composition, and co-administered substances could substantially alter these parameters. Potent CYP3A4 inhibitors (certain antifungals, ritonavir, clarithromycin, grapefruit juice) would be expected to increase flubromazolam exposure and prolong its effects.[12]
Neuroscience[edit]
Where it acts
Flubromazolam amplifies inhibitory GABA signaling across the central nervous system.[2][13] Its sedative and amnestic effects are primarily driven by GABA-A receptors in cortical and thalamic regions that govern arousal and memory. Anxiety relief involves receptors concentrated in limbic structures including the amygdala and hippocampus, while muscle relaxation engages spinal cord receptors.citation needed
The pronounced memory blackouts — partial amnesia exceeding 24 hours at 0.5 mg[3] — reflect disruption of hippocampal processes required to encode new memories into long-term storage.[13]
Tolerance and neuroadaptation
Chronic use triggers the brain's compensatory response: GABA-A receptors are downregulated and internalized, while excitatory glutamate signaling (via NMDA and AMPA receptors) becomes sensitized.[14][13] This rebalancing is the molecular basis of tolerance — more drug is needed for the same effect.
When the drug is removed, the now-disinhibited excitatory system produces a hyperexcitable state: anxiety, insomnia, and potentially life-threatening seizures. The lethal synergy with opioids reflects the co-location of GABA-A and μ-opioid receptors on brainstem neurons that control breathing.[15][16]
Key unknowns include whether flubromazolam shows preference for specific GABA-A receptor subtypes (which would determine the balance between sedation, amnesia, and anxiety suppression), why its time to peak concentration (~8 hours) is so slow, and whether chronic use produces lasting brain changes beyond those seen with prescribed benzodiazepines. The greater-than-24-hour amnesia at 0.5 mg exceeds typical reports for prescribed triazolo compounds at comparable doses — whether this reflects a pharmacokinetic property or enhanced amnestic potency remains uninvestigated.
Subjective Effects[edit]
Flubromazolam produces a slow-building wave of sedation and anxiety dissolution that deepens over hours rather than minutes, reflecting its unusually long time to peak effect. At low doses the experience is dominated by calm and mild euphoria; at common doses, heavy sedation and pronounced memory blackouts take over — users frequently cannot accurately assess their own level of impairment, a phenomenon described as "delusions of sobriety" that drives compulsive redosing.[3] Set and setting modulate the anxiolytic and euphoric components, but the sedative and amnestic effects are relatively context-independent at common doses.
Compared to alprazolam, flubromazolam is active at roughly one-quarter to one-half the dose with a substantially longer duration of both subjective effects and residual impairment. Relative to clonazolam — its closest comparator among designer benzodiazepines — it appears to produce comparable per-milligram potency but with a more gradual onset and more protracted course.[5]
Effect Grid
At common doses (150–250 µg oral), the characteristic flubromazolam profile fully manifests: pronounced sedation, significant anxiolysis, and clear muscle relaxation. Euphoria is frequently reported at this range. Emotional responses are blunted and social inhibitions markedly reduced. Disinhibition and increased talkativeness may occur.
Physically, motor impairment becomes substantial — coordination is visibly affected and gait may become unsteady. Slurred speech is possible. Drowsiness is prominent and many users will fall asleep during the experience.
Anterograde amnesia becomes a significant feature at this range — users may have incomplete or absent recall of events during the experience. Thought deceleration and disorganisation are pronounced. The risk of compulsive redosing is elevated due to delusions of sobriety. Total duration typically spans 10–14 hours with residual impairment persisting well beyond subjective effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sleep-transition hallucinations · Vestibular distortion · Depth perception distortion
Bodily heaviness · Dizziness · Nystagmus (eye wobbles) · Body high · Breathing alteration · Nausea · Nausea suppression
Breathing alteration · Nausea · Nausea suppression
Cognitive fatigue · Focus suppression · Information processing suppression · Memory suppression · Thought disorganization · Creativity suppression · Language suppression · Memory fragmentation · Motivation suppression · Suggestibility enhancement · Confusion · Compulsive redosing urge · Cognitive euphoria · Amnesia · Delirium
Memory suppression · Thought disorganization · Creativity suppression · Language suppression · Memory fragmentation · Motivation suppression · Confusion · Compulsive redosing urge · Cognitive euphoria · Amnesia · Delirium
Emotional lability · Anxiety · Dysphoria
Depersonalization · Derealization
Timeline
First alerts emerge as a subtle sense of relaxation and mild heaviness. The onset is gradual and easily overlooked, particularly by tolerant users.
Anxiolysis and sedation build progressively. Muscle relaxation becomes noticeable. Thought processes begin to slow.
Full sedation, pronounced amnesia, and maximum muscle relaxation. Euphoria is most prominent during the first hours of the peak. The unusually prolonged Tmax (~8 hours) means peak effects may not fully manifest until several hours into the experience.
Sedation remains substantial but intensity begins to diminish. Amnesia and motor impairment persist at clinically significant levels. Cognitive dulling continues.
Gradual return of cognitive clarity, though residual sedation, mild amnesia, and muscle relaxation linger. Motor coordination remains impaired. The long half-life (10–20 hours) means pharmacological activity continues well into this phase.
Residual drowsiness, mild cognitive fog, and subtle muscle relaxation may persist for 12–48 hours after subjective effects resolve. Psychomotor impairment can remain measurable even when the user feels baseline.
⚠ Do not drive or operate heavy machinery for at least 24 hours after last dose, and longer if any residual sedation or cognitive impairment is noticeable.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
Acute toxicity
No lethal dose data have been published for flubromazolam in any species.safety citation needed When used alone, the compound's intrinsic toxicity appears low — consistent with the benzodiazepine class generally, which has a wider safety margin than older sedatives like barbiturates. The first published case report described a severe single-drug poisoning with prolonged unconsciousness, dangerously low blood pressure, and muscle breakdown requiring hospital admission.[17]
Three factors converge to make flubromazolam acutely dangerous despite its class-level safety margin: (1) the sub-milligram active dose range makes accurate dosing extremely difficult in unregulated preparations,[5] (2) amnesia and delusions of sobriety drive compulsive redosing,[3] and (3) synergistic respiratory depression with opioids drives nearly all documented deaths.
Fatality data
No published case establishes flubromazolam as the sole cause of death — all fatal cases have involved co-administered central nervous system depressants. In Victoria, Australia (2018–2022), it was detected in 12 of 133 designer benzodiazepine-associated deaths, always alongside other drugs.[18] In North Carolina (2020–2022), it appeared in counterfeit prescription pills linked to multiple deaths.[19]
Broader surveillance confirms the pattern: US illicit benzodiazepine-involved deaths increased 519.6% from 2019 to mid-2020, with 92.7% involving opioids.[7] Flubromazolam ranked among the top three designer benzodiazepines in adverse events and deaths reported to UNODC.[20] Impaired driving cases where flubromazolam was the sole identified intoxicant confirm substantial psychomotor impairment from the drug alone.[3][21]
Drug supply contamination
Flubromazolam has been detected as an adulterant in unregulated opioid supplies[22] and in counterfeit prescription pills.[19] The WHO specifically noted its "potential to increase unintentional opioid overdoses".[3] Standard fentanyl test strips do not detect benzodiazepines, and no widely validated point-of-care test for flubromazolam exists.[22]
Psychological risks
The dominant psychological risk is anterograde amnesia — memory blackouts lasting more than 24 hours are documented at a single 0.5 mg dose.[3] Combined with delusions of sobriety, this creates a high risk of compulsive redosing — users may take additional doses without memory of prior ingestion.[3]
Disinhibition and loss of behavioral control are consistently reported[11][23] and documented in impaired driving cases.[21] The combination of amnesia, disinhibition, and high potency has led to flubromazolam's identification among designer benzodiazepines with drug-facilitated sexual assault risk.[24]
Severe withdrawal-related psychological symptoms — including anxiety, panic attacks, dissociative symptoms, and perceptual distortions — are reported following cessation of regular use.[3]
Tolerance & dependence
Tolerance to flubromazolam's sedative effects develops rapidly — within days of continuous use.[11] The WHO documented online reports of rapid tolerance onset, noting this pattern "suggests that taking increased doses and developing physical dependence is likely".[3]
The underlying mechanism involves downregulation of GABA-A receptors and compensatory sensitization of excitatory glutamate signaling.[14][13] When the drug is stopped, this imbalance produces withdrawal symptoms including muscle aches, sleep disturbances, severe anxiety, panic attacks, dissociative symptoms, cramping, vomiting, and seizures.[3]
No established long-acting benzodiazepine equivalence dose exists for flubromazolam, making clinical withdrawal management particularly difficult — symptom-based treatment is required.[6] Cross-tolerance with all benzodiazepines, Z-drugs, alcohol, and barbiturates is expected from the shared GABA-A mechanism.
Drug interactions
The primary lethal interaction is with opioids. Synergistic respiratory depression occurs because opioid and GABA-A receptors are co-located on brainstem neurons that control breathing.[15][16] US surveillance shows 92.7% of illicit benzodiazepine-involved deaths involved opioids.[7]
Three factors make this interaction especially hazardous: naloxone does not reverse benzodiazepine-mediated respiratory depression; flubromazolam has been found as an adulterant in unregulated opioid supplies;[22] and the drug's long half-life (10–20 hours) may exceed naloxone's duration of action.
Alcohol produces additive-to-synergistic central nervous system and respiratory depression, documented in polydrug fatality series.[18]
Other central nervous system depressants — including other benzodiazepines, Z-drugs, gabapentinoids, muscle relaxants, antipsychotics, and sedating antihistamines — produce additive or synergistic depression. In English and Welsh coronial cases, flubromazolam co-occurred with at least one other designer benzodiazepine in 48% of cases.[25]
CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, clarithromycin, grapefruit juice) are expected to substantially increase flubromazolam blood levels based on CYP3A4/5 as the primary metabolic pathway.[12]
Kratom (Mitragyna speciosa) was noted as a complicating factor in benzodiazepine withdrawal management via liver enzyme inhibition.[6]
Contraindications
Opioid co-use is an absolute contraindication due to synergistic respiratory depression.[13]
Alcohol and other central nervous system depressants carry absolute contraindication status given documented synergistic lethality.
CYP3A4 inhibitor co-administration is a relative contraindication, as potent inhibitors would be expected to substantially increase flubromazolam exposure.[12]
Pregnancy and breastfeeding: No data exist for flubromazolam specifically. Class-level benzodiazepine concerns include neonatal withdrawal syndrome.[13]
Seizure disorders: While benzodiazepines are anticonvulsant during use, abrupt withdrawal can trigger seizures.[6] Individuals with seizure disorders face compounded risk.
Known benzodiazepine hypersensitivity is an absolute contraindication.
Harm Reduction[edit]
Forms & Identification
Flubromazolam's sub-milligram active dose range means that even small variations in preparation can produce dramatically different effects. Volumetric dosing from a verified solution is the only reliable method — weighing raw powder at this scale requires laboratory-grade equipment beyond what most users possess. Any dose handled as loose powder or broken from a pressed tablet should be treated as imprecise.
Counterfeit pharmaceutical tablets containing flubromazolam have been documented in place of prescription benzodiazepines and opioids. Standard fentanyl test strips do not detect benzodiazepines. Drug checking services that use mass spectrometry or immunoassay-based benzodiazepine strips offer the most reliable identification.
Guidelines
- Test all substances with a drug checking service when possible — point-of-care benzodiazepine immunoassay strips offer a baseline check but cannot confirm specific compounds.
- Use volumetric dosing from a calibrated solution. Do not attempt to measure sub-milligram quantities by eye or with consumer-grade scales.
- Pre-measure a single dose and secure or remove remaining supply before ingesting. Amnesia and delusions of sobriety reliably lead to unintended redosing.
- Write down the time of ingestion and dose on paper and place it somewhere visible — this information may be critical if memory loss occurs.
- Do not drive or operate machinery. Impairment may persist well beyond 24 hours and is not reliably self-assessed.
- Do not use alone. A sober companion should be briefed on what to watch for and when to call for help.
- Allow at least 48 hours for full recovery before any activity requiring coordination, judgment, or memory.
Set & Setting
The slow onset (peak effects may not arrive for 6–8 hours) makes patience essential — redosing before the full effects manifest is a leading cause of dangerous overdose with this compound. A familiar, safe environment with a sober companion present is strongly advised. The pronounced amnesia and delusions of sobriety mean that a trusted person who can prevent redosing is more important with this substance than with most other benzodiazepines.
Aftercare & integration. Memory gaps are expected and may span hours to days. Reviewing notes, messages, and speaking with anyone present during the experience can help reconstruct the timeline. Residual sedation, cognitive fog, and impaired coordination may persist for 24–48 hours after the last dose.
Prioritize sleep, hydration, and light nutrition during recovery. Avoid driving, important decisions, or additional substance use until full cognitive clarity has returned. If memory blackouts, disinhibited behavior, or unplanned redosing occurred, honest self-assessment of the experience is important for future risk decisions.
Recovery & Support
Flubromazolam dependence requires medical supervision to manage safely — abrupt cessation can cause seizures. No established equivalence dose exists for converting flubromazolam to a longer-acting benzodiazepine for taper, so withdrawal management is symptom-guided and must be individually titrated by a clinician experienced in benzodiazepine withdrawal.
Peer support communities and addiction medicine specialists can provide critical help. The Benzodiazepine Information Coalition (benzoinfo.com) offers resources specifically for benzodiazepine dependence and withdrawal. SAMHSA's National Helpline (1-800-662-4357) provides free referrals in the United States.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes very slow, shallow, or stops
- Blue or grey lips and fingertips
- Unresponsive to loud voice or sternal rub
- Seizure activity (especially during withdrawal)
- Prolonged loss of consciousness beyond expected sedation
Immediate steps:
- 1. Call emergency services immediately if breathing is impaired or the person is unresponsive.
- 2. Place the person in the recovery position (on their side) to protect the airway.
- 3. Do not induce vomiting.
- 4. Stay with the person and monitor breathing until help arrives.
What to tell the dispatcher:
- The substance taken (flubromazolam, a designer benzodiazepine), estimated dose and time.
- Current symptoms — breathing rate, consciousness level, skin color.
- Whether any other substances were taken.
- Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agents:
- Naloxone does not reverse benzodiazepine effects but should be administered if opioid co-exposure is suspected.
- Flumazenil can reverse benzodiazepine sedation but carries serious risks including seizures, especially in dependent users — it is not recommended for routine use.[26]
- Flubromazolam's long half-life (10–20 hours) may outlast reversal agents, requiring extended monitoring.
Legal Status[edit]
Flubromazolam is internationally controlled under Schedule IV of the 1971 United Nations Convention on Psychotropic Substances following the Commission on Narcotic Drugs' 64th session vote in June 2021.[10] The compound has no approved therapeutic use in any jurisdiction and has been independently scheduled by multiple countries in response to documented harms.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Permanent placement effective ~April 1, 2026; preceded by temporary Schedule I (December 2022, extended July 2023)[10][27] |
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Amendment effective May 2017citation needed |
| Australia | Schedule 9 — Prohibited substance | Federal scheduling since approximately 2016[9] |
| Canada | Schedule IV (CDSA) | Controlled under Benzodiazepines and Other Targeted Substances Regulationscitation needed |
| Switzerland | Controlled | Scheduled since December 2015citation needed |
| Sweden | Scheduled | National scheduling circa 2015citation needed |
| United Nations | Schedule IV (1971 Convention) | CND 64th session, June 2021[10] |
Prior to temporary scheduling in the United States (December 2022), flubromazolam was potentially subject to the Controlled Substances Analogue Enforcement Act as a structural analogue of scheduled triazolobenzodiazepines, though enforcement under the Analogue Act was inconsistent.[5]
references
- [1] ^abWaters LJ, Manchester KR, Maskell P, Haegeman C, Haider S (2017) The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines — Science & Justice doi:10.1016/j.scijus.2017.12.004
- [2] ^abcZhu S, Sridhar A, Teng J, Howard RJ, Lindahl E, Hibbs RE (2022) Structural and dynamic mechanisms of GABAA receptor modulators with opposing activities — Nature Communications doi:10.1038/s41467-022-32212-4
- [3]
- [4]
- [5]
- [6] ^abcdButler M, Pirkle J, Carmichael A, Carlson-Dexter P, Rosella T (2025) Successful symptom-based management of active withdrawal from multiple illicit benzodiazepines — BMJ Case Reports doi:10.1136/bcr-2025-266077